Iris Lo joined the Board of FSGV in 2015 and has been a volunteer on the Finance Committee since the beginning of 2014. Iris is the Chief Financial Officer of Novoheart Holdings Inc., a biotechnology start-up that she helped take public in 2017.
Prior to Novoheart, Iris was the Director, Corporate Development and Analysis at Cardiome Pharma Corp. where she managed corporate finance, corporate development transactions, and financial planning and analysis. She previously worked for PwC in Transaction Services, specializing in in-bound and out-bound M&A deals for private equity and corporate clients. Iris is a CPA, CA and a graduate of the Sauder School of Business.